CurrentEndo
Get Weekly

CurrentEndo coverage · page 39 of 55

Diabetes, Obesity and Metabolism

Briefs 1,521–1,560 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Dark tea consumption is associated with a reduced risk of dysglycaemia and increased urinary glucose and sodium excretion in Chinese adults

    Cross-sectional studyT2D & other

  2. Diabetes Obes Metab

    ADO09, a co‐formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes

    Randomized controlled trialT1D

  3. Diabetes Obes Metab

    Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID ‐19 patients with type 2 diabetes: A target trial emulation study

    Research articleT2D & other

  4. Diabetes Obes Metab

    Efficacy, adherence and persistence of various glucagon‐like peptide‐1 agonists: nationwide real‐life data

    Cohort studyT2D & other

  5. Diabetes Obes Metab

    Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data

    Cohort studyT2D & other

  6. Diabetes Obes Metab

    Metabolically healthy obesity and left ventricular geometric remodelling in Chinese children

    Cross-sectional studyObesity

  7. Diabetes Obes Metab

    Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study

    Cohort studyT2D & other

  8. Diabetes Obes Metab

    Trends in hospitalization for cardio‐renal disease and mortality in people with type 1 diabetes in England, 2009–2019

    Cross-sectional studyT1D

  9. Diabetes Obes Metab

    Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial

    Randomized controlled trialObesity

  10. Diabetes Obes Metab

    Associations of childhood and adulthood body size, and child‐to‐adult body size change with adult telomere length

    Cohort study

  11. Diabetes Obes Metab

    Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users

    Cohort studyComplications

  12. Diabetes Obes Metab

    Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial

    Secondary analysisT2D & other

  13. Diabetes Obes Metab

    Mortality patterns in Dutch diabetes outpatients

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study

    Cohort studyLipids & liver

  15. Diabetes Obes Metab

    Efficacy and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: The INITIATION study

    Cohort studyT2D & other

  16. Diabetes Obes Metab

    Body weight change associated kidney outcomes of sodium–glucose cotransporter new users

    Cohort studyT2D & other

  17. Diabetes Obes Metab

    Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada

    Cross-sectional studyTechnology

  18. Diabetes Obes Metab

    Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy

    Diagnostic or prognostic studyT2D & other

  20. Diabetes Obes Metab

    Cost‐effectiveness analysis of a digital diabetes‐prevention programme versus an in‐person diabetes‐prevention programme in people with prediabetes in the United States

    Cohort studyT2D & other

  21. Diabetes Obes Metab

    Follow‐up and monitoring programme in children identified in early‐stage type 1 diabetes during screening in the general population of Italy

    Guideline or statementT1D

  22. Diabetes Obes Metab

    Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial

    Randomized controlled trialT2D & other

  23. Diabetes Obes Metab

    Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis

    Meta-analysisObesity

  24. Diabetes Obes Metab

    Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis

    Meta-analysisT2D & other

  25. Diabetes Obes Metab

    An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes

    Randomized controlled trialT2D & other

  26. Diabetes Obes Metab

    Effectiveness of switching from dipeptidyl peptidase‐4 inhibitor to oral glucagon‐like peptide‐1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching

    Cohort studyT2D & other

  27. Diabetes Obes Metab

    Individual treatment effects of sodium‐glucose co‐transporter‐2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real‐world data

    Cohort studyT2D & other

  28. Diabetes Obes Metab

    Time trends in hypertension and diabetes prevalence by body mass index categories in Brazilian adults from 2006 to 2023

    Cross-sectional studyT2D & other

  29. Diabetes Obes Metab

    Incidence and progression of diabetic retinopathy in patients treated with glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter 2 inhibitors: A population‐based cohort study

    Cohort studyComplications

  30. Diabetes Obes Metab

    The causal relationship between plasma protein‐to‐protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study

    Research articleT2D & other

  31. Diabetes Obes Metab

    Clinical factors influencing the success rate of radioiodine treatment for Graves' disease

    Cohort studyThyroid

  32. Diabetes Obes Metab

    Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: A population‐based cross‐sectional screening study

    Cross-sectional studyT2D & other

  34. Diabetes Obes Metab

    Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

    Meta-analysisComplications

  35. Diabetes Obes Metab

    Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis

    Secondary analysisT2D & other

  36. Diabetes Obes Metab

    Bariatric surgery and all‐cause mortality: A methodological review of studies using a non‐surgical comparator

    Research articleObesity

  37. Diabetes Obes Metab

    Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity

    Randomized controlled trialObesity

  38. Diabetes Obes Metab

    Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower visceral and hepatic lipid content in recent‐onset type 1 diabetes and type 2 diabetes

    Cross-sectional studyT2D & other

  39. Diabetes Obes Metab

    Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status

    Cohort studyT2D & other

  40. Diabetes Obes Metab

    Development and validation of 10‐year risk prediction models of cardiovascular disease in Chinese type 2 diabetes mellitus patients in primary care using interpretable machine learning‐based methods

    Cohort studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,521–1,560 of 2,200, newest first